RNAi Therapeutics
Scientists use RNAi biological phenomena to study particular genes and their functions. The main hurdle in using RNAi for therapeutic gene silencing is the effective intracellular delivery of siRNA into the cell or tissue. The capability of siRNAs to mediate post-transcriptional gene silencing in mammalian cells and tissues, as well as its successful use to prevent expression of target mRNA has recently led to the development of a new methodology for novel drug discovery. Several pharmaceutical and biotechnology companies are currently investigating the possible use of synthetic siRNA for inducing RNAi in vivo, its use in animal models, and in RNAi-based therapeutics. Small RNA molecules, such as siRNA, shRNA, and microRNA have been regarded as potential therapeutic agents to target multiple misregulated cellular processes therefore it is theoretically possible that RNAi can be utilized to treat any disease associated with over expression of specific genes. In fact, there are many reports in the literature that address the potential therapeutic application of RNAi to specifically target genes involved in multiple diseases including various forms of cancer, Alzheimer’s, and a number of inflammatory and virally-associated diseases. However, a number of major difficulties associated with inefficient delivery of functional RNA molecules into cells and the reduced biostability of unmodified RNA must be overcome. Therefore, our research is focused on the development of efficient in vivo reagents and RNAi delivery technologies. Efficient and organ-specific delivery of synthetic oligonucleotide molecules is currently a key limiting step to enable siRNA- and microRNA-based therapeutic approaches.

Transfection Resource

siRNA Transfection | Transfection Methods | Stable Transfection | RNAi | siRNA Library Screening | RNAi Therapeutics | Cell Transfection | In Vivo Transfection Reagents | Cell Line Specific Transfection Reagents

Featured Products

In Vivo Transfection Reagents | Fibroblast Cells Transfection Reagent | Astrocyte Cells Transfection Reagent | HEK-293 Transfection Reagent | MEF Transfection Reagent | HepG2 Transfection Reagent | CHO Reagent | MDA-MB Transfection Reagent | Cos7 Transfection Reagent | A549 Transfection Reagent | NIH3T3 Reagent | HUVEC Transfection Reagent | LNCaP Transfection Reagent | MCF-7 Transfection Reagent | PC-12 Reagent

Altogen Biosystems

Altogen Biosystems is a life sciences company dedicated to the development, marketing and manufacture of cell type specific transfection reagents. Efficient delivery of DNA, RNA, siRNA, and microRNA enabled by advanced formulation of reagents and peculiar design of protocols.

Altogen Biosystems offers a complete transfection system for a broad range of cell lines. All reagents are functionally tested to be highly reproducible, serum compatible, induce low toxicity, and can be used for co-transfection experiments, and high throughput applications.